This study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.
This study is looking at assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.
The official record suggests in-person participation through a hospital, with sites including Ima Clinical Research Phoenix (Alea) /ID# 278047, Advanced Research Center /ID# 273474 in Anaheim, and Axiom Research /ID# 273482 in Colton. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually matching the main diagnosis and being able to follow the planned visits or tasks, while common reasons not to take part include active substance or alcohol problems that could affect the results and major medical issues that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
This study may matter because it is evaluating ABBV-932 in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring digital app or tool for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by AbbVie. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
This study may involve digital app or tool, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is Phase 2. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.